Analyst firms · William Blair · NTLA

William Blair NTLA price target and rating history

Intellia Therapeutics Inc. (NTLA) · Health Care

William Blair rates Intellia Therapeutics Inc. (NTLA) Outperform with a $144 price target, as of its latest action on Mar 2, 2026. It has published 4 rating actions on NTLA since February 2022, including 1 upgrade and 1 downgrade.

Current rating
Outperform
Price target
$144
Median target, all firms
Too few
Actions on NTLA
4

Every William Blair rating on NTLA

How other firms rate NTLA

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysUnderweight$8Oct 6, 2026
Wolfe ResearchUnderperform$9Jul 16, 2026
William BlairOutperformMar 2, 2026

Questions about William Blair and NTLA

What is William Blair's price target for NTLA?
William Blair's latest stated price target for Intellia Therapeutics Inc. (NTLA) is $144, from its action on Feb 18, 2022.
What is William Blair's rating on NTLA?
William Blair rates NTLA Outperform, a bullish rating, as of Mar 2, 2026.
When did William Blair last change its view on NTLA?
On Mar 2, 2026, William Blair upgrades to Outperform from Mkt Perform.

More NTLA rating histories

All William Blair ratingsNTLA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.